BMO Capital on Alnylam Pharmaceuticals (ALNY): 'Strong ATTR Outlook With Limited Readthrough From Eplontersen'
Tweet Send to a Friend
BMO Capital analyst David Lebowitz reiterated an Outperform rating and $318.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
